Global Drug Discovery Outsourcing Market: Key Developments
In January 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. entered into a collaboration agreement with Insilico Medicine, an end-to-end artificial intelligence (AI)-driven drug discovery and development company to advance the discovery and development of drugs targeting a number of different targets globally through the use of AI technology.
In January 2022, Evotec partnered with Eli Lilly and Company for the drug discovery of metabolic diseases. Under the agreement, Evotec will identify potential drug candidates to treat diabetes and chronic kidney diseases from targets selected by either of the companies.
In September 2021, Eurofins and Liverpool ChiroChem Ltd. teamed up to offer improved chemical expertise by accessing Liverpool ChiroChem’s PROTAC linker molecules to augment the unified drug discovery platform, DiscoveryOne.
In July 2022, GenScript ProBio and DAAN Bio Therapeutics entered into a strategic cooperation regarding the development of innovative drug development and discovery.
Global Drug Discovery Outsourcing Market: Key Companies Insights
The global drug discovery outsourcing market is highly competitive. This is attributed to the rise in adoption of outsourcing services, as a result, players in the market are focusing on developing and launching novel drugs in the market.
Some of the key players in the global drug discovery outsourcing market are Curia, Genscript, Evotec, Eurofins Scientific, Laboratory Corporation of America Holdings, among others.
Drug Discovery Outsourcing Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients